Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05532735 · ClinicalTrials.gov registry record · Phase 2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
A Phase 2 study of Retinal Vein Occlusion, sponsored by Annexin Pharmaceuticals AB.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 7
- Study locations
NCT05532735: Completed Phase 2 study of Retinal Vein Occlusion, sponsored by Annexin Pharmaceuticals AB.
NCT05532735 is a Phase 2 study of Retinal Vein Occlusion that has completed, run by Annexin Pharmaceuticals AB. The registered enrollment target is 16 participants, below the 858-participant average among 11 other Retinal Vein Occlusion trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05532735, a Phase 2 study of Retinal Vein Occlusion, has completed, sponsored by Annexin Pharmaceuticals AB.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 7
- Study locations
Study Summary
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
Primary Outcome
Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Conditions Studied
Interventions
- BIOLOGICAL ANXV
Study Locations (7)
Texas
- Retina Consultants of Texas - Bellaire
- Valley Retina Institute - McAllen
- Retina Consultants of Texas - San Antonio
Louisiana
- Eye Associates of Northeast Louisiana - West Monroe
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Oklahoma
- Tulsa Retina Consultants - Tulsa
Virginia
- Virginia Retina Center - Warrenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 2 |
What the finished NCT05532735 record still lists
NCT05532735 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 858-participant average among 11 other Retinal Vein Occlusion trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which ANXV is the first listed.
NCT05532735 lists 7 locations in 5 states (Texas, Louisiana, Maryland).
Frequently Asked Questions
What is clinical trial NCT05532735 about?
NCT05532735 is a clinical study titled "Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion". Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
What is the current status of trial NCT05532735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-08-24. Estimated completion is 2024-11-11.
What conditions does trial NCT05532735 study?
This clinical trial studies the following conditions: Retinal Vein Occlusion.
What interventions are being tested in trial NCT05532735?
The interventions under investigation include: ANXV (BIOLOGICAL).
Who is sponsoring clinical trial NCT05532735?
This trial is sponsored by Annexin Pharmaceuticals AB, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05532735 being conducted?
This trial has 7 study locations across Louisiana, Maryland, Oklahoma, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Vein Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05532735's enrollment target sits among peer trials
16 11th of 11 higher than 1 of 11 other Retinal Vein Occlusion trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinal Vein Occlusion trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
COMPLETED · Phase 2
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
National Eye Institute Biorepository for Retinal Diseases
RECRUITING
-
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
RECRUITING · NA
-
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
ACTIVE NOT RECRUITING
-
30g vs 33g Needle for Intravitreal Injections
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI